GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » Interest Coverage

Mustang Bio (Mustang Bio) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Mustang Bio's Operating Income for the three months ended in Dec. 2023 was $-8.86 Mil. Mustang Bio's Interest Expense for the three months ended in Dec. 2023 was $2.80 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Mustang Bio's Interest Coverage or its related term are showing as below:


MBIO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 122.085
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Mustang Bio Interest Coverage Historical Data

The historical data trend for Mustang Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mustang Bio Interest Coverage Chart

Mustang Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only - - - - -

Mustang Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mustang Bio's Interest Coverage

For the Biotechnology subindustry, Mustang Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mustang Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Mustang Bio's Interest Coverage falls into.



Mustang Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mustang Bio's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Mustang Bio's Interest Expense was $-1.31 Mil. Its Operating Income was $-50.73 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.98 Mil.

Mustang Bio did not have earnings to cover the interest expense.

Mustang Bio's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Mustang Bio's Interest Expense was $2.80 Mil. Its Operating Income was $-8.86 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Mustang Bio  (NAS:MBIO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Mustang Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of Mustang Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Mustang Bio (Mustang Bio) Business Description

Traded in Other Exchanges
N/A
Address
377 Plantation Street, Worcester, MA, USA, 01605
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.
Executives
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman director, officer: President and CEO 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach officer: SVP, Fin. & Corp. Controller 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill director 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky director
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Mustang Bio (Mustang Bio) Headlines

From GuruFocus